Featured Lectures

Thursday, March 16

1:30-2:15 pm
James Ewing Lecture
“Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms”

Jedd D. Wolchok, MD, PhD
Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation
Chief, Melanoma & Immunotherapeutics Service
Director, Parker Institute for Cancer Immunotherapy
Associate Director, Ludwig Center for Cancer Immunotherapy and Member, Ludwig Cancer Research
Professor of Medicine, Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center
New York, NY

2:15-3 pm
John Wayne Clinical Research Lecture
“Postoperative Complications and Cancer Recurrence: Dissecting the Role of Neutrophils in the Metastatic Process”

Lorenzo Ferri, MD, PhD
David S. Mulder Chair in Surgery
Professor of Surgery and Oncology
McGill University
Montreal, Quebec, Canada

Friday, March 17

9-9:45 am
SSO Presidential Address
Charting the Course Ahead for the Society of Surgical Oncology: "The Future Ain't What It Used To Be"
Daniel G. Coit, MD
Professor of Surgery, Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center
New York, NY

Saturday, March 18

9:45-10:30 am
American Cancer Society/SSO Basic Science Lecture
"Obesity, White Adipose Inflammation and Breast Cancer"
Andrew J. Dannenberg, MD
Henry R. Erie, MC-Roberts Family Professor of Medicine
Weill Cornell Medical College
New York, NY


Featured Lectures Bios
 

    Daniel G. Coit, MD
Professor of Surgery, Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center
New York, NY


Dr. Daniel Coit, MD, FACS received his medical degree in 1976 from the University of Cincinnati. After completing a surgical residency at the New England Deaconess Hospital, and surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center, he joined the MSKCC faculty in 1985. Since that time, he has developed a specific academic, research and clinical interest in the care of patients with melanoma and gastric cancer, publishing over 200 peer reviewed articles, reviews, and book chapters on those subjects. Dr. Coit’s interest in melanoma is focused primarily on the clinical significance of regional lymph nodes, both clinical nodal metastasis, and those found in sentinel lymph nodes, either microscopic or submicroscopic. In gastric cancer, his interest is focused on optimal pre-treatment risk assessment, with an emphasis on the important role of laparoscopy and examination of peritoneal cytology prior to surgical resection.

Dr. Coit has an abiding interest in surgical education, having been nominated as the outstanding teacher at MSKCC by surgical fellows on three separate occasions. He chaired the SSO training committee, responsible for overseeing all surgical oncology fellowship training programs. He is currently the President of the SSO. He served on the Surgical Oncology Advisory Committee to the American Board of Surgery. He was the Chief of the Gastric & Mixed Tumor Service at MSKCC from 1997-2003. He currently serves as the Co-Leader of the Melanoma Disease Management Team, and Chairs the NCCN Melanoma Committee. He also serves as the Co-Leader of the MSKCC Gastric Cancer Disease Management Team. He is a member of the AJCC staging committees for both melanoma and upper GI cancer.
 

   Andrew J. Dannenberg, MD
Henry R. Erie, MC-Roberts Family Professor of Medicine
Weill Cornell Medical College
New York, NY


Andrew J. Dannenberg, MD is the Henry R. Erle, MD-Roberts Family Professor of Medicine at the Joan & Sanford I. Weill Medical College of Cornell University and Associate Director of Cancer Prevention at the Sandra and Edward Meyer Cancer Center.  Dr. Dannenberg received his medical degree from Washington University in St. Louis and served as a medical resident and gastroenterology fellow at The New York Hospital-Cornell Medical Center.  His laboratory has focused on elucidating the mechanisms underlying the inflammation-cancer connection with an emphasis on prostaglandin biology. Currently, a bench to bedside effort is being made to understand the link between obesity and cancer with an emphasis on adipose inflammation and related biomarkers.  The long-term goal of this research is to develop evidence-based approaches to reduce the risk of cancer or inhibit its progression.  Dr. Dannenberg has authored more than 200 scientific articles, as well as edited several books and journals.  In 2011, he was awarded the American Association for Cancer Research-Prevent Cancer Foundation award for excellence in cancer prevention research.  He is a member of the Association of American Physicians (AAP), the American Society for Clinical Investigation (ASCI), and the American Association for Cancer Research (AACR).
 

Lorenzo Ferri, MD, PhD
David S. Mulder Chair in Surgery
Professor of Surgery and Oncology
McGill University
Montreal, Quebec, Canada


Dr. Ferri is the David S. Mulder Chair in Surgery and a Professor in the Departments of Surgery and Oncology at McGill University in Montreal, Canada. A Boston native, Dr. Ferri moved north of the border to complete undergraduate, medical studies, and surgical residency at McGill University. During a residency, he obtained a PhD investigating neutrophil biology in states of systemic inflammation. Following fellowships in Minimally Invasive Surgery (McGill), Thoracic Surgery (University of Toronto), and Esophageal Surgery (University of Hong Kong), he was recruited back to McGill University in 2005 where he currently is director of the Division of Thoracic Surgery and heads the McGill University program in upper gastrointestinal cancer.

Dr. Ferri is an independent investigator with active basic science, translational and clinical research programs, all concentrated primarily on malignancies of the chest and foregut with more than 75 manuscripts published to date. He is the recipient of numerous peer review grants, including the Canadian Institutes of Health Research and Canadian Cancer Society, for his work into the inflammatory basis of cancer metastasis. Through this work he has identified the important role of bacterial antigens - pattern recognition proteins (TLRs and NODs) and host neutrophils/Neutrophil Extracellular Traps in propagating cancer dissemination, thus representing a new paradigm in the metastatic process.
 

    Jedd D. Wolchok, MD, PhD
Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation
Chief, Melanoma & Immunotherapeutics Service
Director, Parker Institute for Cancer Immunotherapy
Associate Director, Ludwig Center for Cancer Immunotherapy and Member, Ludwig Cancer Research
Professor of Medicine, Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center
New York, NY

Dr. Wolchok is the Lloyd J. Old and Daniel K. Ludwig Chair in Clinical Investigation, Chief of the Melanoma and Immunotherapeutics Service, Attending Physician at Memorial Sloan Kettering Cancer Center (MSK) with an expertise in the treatment of metastatic melanoma. He received his undergraduate degree from Princeton University and both MD and PhD from New York University, where he also fulfilled his residency program.  He completed his fellowship at MSK and remained on faculty with an appointment in the Melanoma and Immunotherapeutics Service, which he now leads. Dr. Wolchok has helped establish MSK as a leader in the discovery and treatment of cancers with novel immunotherapies. Dr. Wolchok was instrumental in the clinical development leading to the approval of ipilimumab for advanced melanoma and recently designed and led a global phase 3 trial of combined checkpoint blockade for melanoma. He has been at the forefront of cancer immunotherapy, as an active clinician scientist exploring innovative immunotherapeutic strategies in laboratory models and as a principal investigator in numerous pivotal clinical trials.  In 2011, he established the Immunotherapeutics Clinical Core, a specialized phase 1 outpatient unit at MSK that is focused on the conduct of novel immunotherapy trials, with a specific emphasis on pharmacodynamic biomarker identification. This group treats patients with a broad spectrum of malignancies and has become a model for similar efforts by other major cancer centers throughout the world.

  •  
    • SSO Exposition Management
    • SPARGO, Inc.
    • Toll Free (800) 564-4220
    • Phone:  (703) 631-6200
    • Fax (703) 563-2691
    • Emailssoexhibits@spargoinc.com